The receptor for calcitonin-gene-related peptide (CGRP) is a heterodimer formed by calcitoninreceptor-like receptor (CRLR), a type I1 (family B) G-protein-coupled receptor, and receptoractivity-modifying protein 1 (RAMPl), a singlemembrane-pass protein. It is likely that the first seven or so amino acids of CGRP (which form a disulphide-bonded loop) interact with the transmembrane domain of CRLR to cause receptor activation. T h e rest of the CGRP molecule falls into three domains. Residues 28-37 and 8-18 are normally required for high-affinity binding, while residues 19-27 form a hinge region. The 28-37 region is almost certainly in direct contact with the receptor; 8-1 8 may make additional receptor contacts or may stabilize an appropriate conformation of 28-37. It is likely that these regions of CGRP interact both with CRLR and with the extracellular domain of RAMPl .
Introduction
Calcitonin-gene-related peptide (CGRP) is an abundant 37-amino-acid neuropeptide. It forms a family with calcitonin, amylin and adrenomedullin. While these peptides have only limited sequence identity, they share a number of structural features: a six (or seven for ca1citonin)-amino-acid ring formed by a disulphide bond at their N-termini, an amphipathic a-helix and a C-terminal amide [l] (Figure 1 ). In view of the similarity of their structures, it is not surprising that they show cross-reactivity at each other's receptors. The receptor for CGRP is a heterodimer between a type 11 G-protein-coupled receptor (GPCR), calcitonin-receptor-like receptor (CRLR), and a single-pass transmembrane protein, receptor-activity-modifying protein 1 (RAMPl). The receptor for adrenomedullin is formed by a dimer between CRLR and RAMP2, a homologue of RAMPl . A second adrenomedullin receptor is formed by the interaction of CRLR with a third member of the RAMP family, RAMP3 [2] . There is pharmacological evidence for a second subtype of CGRP receptor, the CGRP, receptor, but its molecular nature remains unclear [3] . T h e CRLR-RAMP1 complex forms the CGRP, receptor.
In view of the novel heterodimeric structure of the CGRP and adrenomedullin receptors, the molecular nature of the interaction between the peptides and their receptors is of considerable interest. This review will focus on the interaction of CGRP with RAMP1-CRLR, in order to suggest mechanisms that might be involved.
Structure of CGRP
CGRP has been examined by N M R and other physical techniques. Its N-terminus is constrained by a disulphide bond between residues 2 and 7. In aqueous solution, the rest of the molecule shows little secondary structure. However, in more hydrophobic solvents there is good evidence for an a-helix between residues 8 and 18 [4, 5] , followed by either a p-or a y-turn in the region of residues 19-22 [6,7] . There then follows a largely unstructured section of the molecule. However, the C-terminus appears to show more order, with several studies noting turns in the regions of residues 28 and 30, and also 32 and 34 [5, 6, 8, 9] .
There is evidence that long-range interactions exist between different parts of the molecule; an NMR study concluded that alanine substitutions fragment that still binds with high affinity but which is an antagonist [12] . Thus residues 1-7 (which includes the disulphide-bonded loop) activate the receptor. It has been suggested that two linear analogues of CGRP (in which the cysteines are derivatized with either acetamidomethyl or ethylamide groups) are selective agonists for the CGRP, receptor, but as these are partial agonists (at least under some circumstances), their use is controversial [3] . Little work has been done to probe the detailed structural requirements of this part of the molecule.
Residues &I 8
Residues 8-18 of CGRP form a potential amphipathic a-helix [13] . Its deletion causes an approx. 100-fold loss of affinity (Table 1) . By contrast, this region can be replaced by various amphipathic sequences with relatively little loss of affinity [13] .
While some disruption of helical structure may be tolerated by this region, gross changes, such as the introduction of a proline residue, lead to a large reduction in affinity [l] .
T h e helix has two positively charged arginines at positions 11 and 18. Replacement of either of these individually with alanine produces only modest decreases in affinity ( < 5-fold); however, a double alanine substitution causes a > 100-fold decrease in affinity ([14,15] ; Table 1 ). Thus, while individually the residues can compensate for each other in promoting high-affinity binding, one or other must be present to allow an effective interaction with the receptor. In principle, the arginine side chains could interact either with other amino acids (either on the receptor or elsewhere on the peptide) or with solvent water molecules, orientating the helix so that its hydrophobic face is in contact with the receptor. This
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Shaded residues have been implicated in receptor binding. 
Residues 28-37
Residues 28-37, by themselves, show only weak binding to the CGRP receptor (Table 1) . However, by making a few amino acid substitutions, a high-affinity antagonist can be generated [9, 17] ( Table 1) . These appear to work by stabilizing a high-affinity conformation of the peptide. Presumably in full-length CGRP the helix comprising residues 8-18 induces this conformation in the C-terminus, either directly or as a consequence of its own receptor interactions. The key amino acids are Thr3', Val32, Gly33 and Phe37 with a C-terminal amide. Bends centred on residues 29 and 34 maximize the solvent exposure of the side chain of Thr3", and place it 8 A from the side chain of Val3' and 17 A from the side chain of Phe37. It has been suggested that these amino acids are in direct contact with the receptor [9] ; presumably Gly33 plays a structural role in holding the peptide in an appropriate conformation, perhaps in a sterically confined pocket.
Structure-activity studies on CRLFURAMP I
Little is known about how either CGRP or adrenomedullin interact with their receptors. In human CRLR, the first 18 amino acids are required for adrenomedullin (but not CGRP) binding [18] . Asp117, close to the start of the first transmembrane helix, is a putative glycosylation site in human CRLR. It actually plays little part in glycosylation, but its mutation to alanine, glutamine, threonine or proline (but not aspartic acid) impairs CGRP binding and signal transduction without greatly altering membrane expression [19] , Adrenomedullin binding and transduction are also impaired by mutating this site [20] . The above data relate entirely to ligand interactions with the extracellular N-terminus of CRLR. It would be surprising if CGRP and adrenomedullin made no contacts with other parts of CRLR, i.e. the extracellular loops or the transmembrane domain. It is possible that the ligand N-terminus may interact with the transmembrane regions, as conformational changes in the latter are responsible for receptor activation. There is considerable evidence for multiple contacts between other type I1 GPCRs and their ligands. For example, it has been suggested that parathyroid hormone makes contact with both the N-terminus and the juxtamembrane region of the receptor [21] . There are also key hydrophilic residues within the transmembrane regions in this and other receptors, which are essential for ligand binding and receptor activation [22] . There are over 20 hydrophilic amino acids within the transmembrane domain of CRLR, with a particular concentration in the first two transmembrane helices. In helix 1 there is a distinct hydrophilic face. Preliminary data from an alanine scan suggest that this is not involved in receptor activation; perhaps it presents the other face of the helix as a RAMP interaction site.
The mechanism of action of the RAMPs in CGRP/adrenomedullin binding is unknown. Studies with chimaeric RAMPs have shown that the N-terminus of RAMPl is the key determinant for expression of CGRP binding [23] ; this would be expected to interact with the N-terminus of CRLR. In human RAMPl, substituting the tryptophan at position 74 with the lysine found in rat RAMPl confers the lower-affinity, rat CRLRRAMPl pharmacology for binding of the nonpeptide CGRP antagonist BIBN4096BS [24] . Residues 86-92 of human RAMP2 and 59-65 of human RAMP3 are needed for adrenomedullin binding [25] ; the data from that study suggest that the main epitope of RAMPl needed for CGRP binding is between residues 76 and 124. The RAMPs may act allosterically on the N-terminus of CRLR, or they may physically form part of the binding site. In support of the latter possibility, CGRP and adrenomedullin can be cross-linked to RAMPl or RAMP2 in addition to CRLR [26, 27] . Both CGRP and adrenomedullin have been reported to label 17 kDa bands in cross-linking experiments conducted on a variety of tissues ; these bands are the size expected for RAMPs [ 28,291. Little is known about the structure of RAMPs. We have recently expressed the extracellular domain of RAMPl as a glutathione S-transferase fusion protein in Escherichia coli. T h e protein appears as inclusion bodies. These can be solubilized in 6 M guanidinium hydrochloride in the presence of a reducing agent and then diluted into a refolding buffer containing an oxidizing agent to give a protein that is soluble at concentrations in excess of 5 mg/ml. This will allow us to determine the structure of the extracellular domain of RAMPl.
A model of CGRP binding?
Given what is known about type I1 GPCR-ligand interactions and the structure of CGRP, it is tempting to suggest that there are several points of contact. Residues 8-18 and 27-37 of CGRP may interact mainly with a binding pocket made up of the N-termini of CRLR and RAMPl, whereas residues 1-7 and perhaps the N-terminal portion of residues 8-18 may interact with the juxtamembrane regions of CRLR.
CGRP, receptors
Little has been done to characterize the structural requirements for CGRP binding to CGRP, receptors. However, it is instructive to compare the affinities of various ligands for CGRP, and CGRP, receptors (Table 1) . There is a correlation between the values, albeit with the affinities for CGRP, being about an order of magnitude lower than those for CGRP,. Rorabaugh et al. [30] suggested that the differences between the receptors could be explained by tissue factors such as proteases. However, it is also possible that one or more of the main ligand-receptor contacts is deficient compared with the CGRP, receptor, resulting in the lower affinities.
It is clear that more work is required to understand the unique heterodimers formed by RAMPs with type I1 GPCRs. 
